This suggests that vimentin-positive gliomas may require more aggressive treatment strategies, and future research is exploring whether vimentin expression could serve as a predictive biomarker for targeted therapies aimed at inhibiting mesenchymal transition in gliomas [134]. This evidence concerns the gene VIM and central nervous system cancer.